EDTXF
Spectral Medical Inc.·Healthcare
1.01
0.299%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.5352W H: $1.31
EDTXF NEWS
newsfilecorp.com
Apr 1
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 1, 2026) - Spectral Medical Inc. (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, will be participating in the 2026 Bloom Burton & Co. Healthcare Investor Conference, which will take place on April 21 and 22 at the Metro Toronto Convention Centre. Dates: Tuesday April 21, 2026-Wednesday April 22, 2026 Time: 8:30 AM - 5:00 PM ET Location: Metro Toronto Convention Centre, North Building255 Front St WToronto, OntarioM5V 2W6 Chris Seto, CEO will be speaking at 1030 AM ET ON Wednesday, April 22nd.
globenewswire.com
Mar 26
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2025 and provided a corporate update.
globenewswire.com
Mar 24
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
TORONTO and DEERFIELD, Ill., March 24, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, and Vantive, a vital organ therapy company committed to pursuing novel diagnostic and therapeutic options for organ failure, today announced the publication of the complete results from the Tigris trial in The Lancet Respiratory Medicine, a leading peer-reviewed journal in critical care medicine. The randomized-controlled trial evaluated the use of Polymyxin B Hemoadsorption (“PMX”) in adults with endotoxic septic shock, providing a more complete picture of patient outcomes, including survival and safety over time.
globenewswire.com
Feb 26
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock.
